復銳醫療科技拓展亞洲業務，在中國天津新設區域辦公室
新成立的復銳醫療科技中國辦公室將開展一系列業務活動，以持續探索與復星醫藥（股票代碼：600196.SH/02196.HK）的潛在合作機會，打造協同生態系統。初步計劃涉及：美容牙科，面部注射填充的NMPA註冊及銷售，區域服務中心及區域倉庫的建設。
復銳醫療科技區域辦公室位於天津自由貿易試驗區，由復星醫藥醫療器械事業部總裁，復銳醫療科技董事長劉毅先生擔任負責人。該項任命體現出復星醫藥對復銳醫療科技在中國及亞太地區業務發展的信心及長遠規劃。
復銳醫療科技中國辦公室通過與復星醫藥合資成立一家新藥基金——天津星魅生物科技有限公司（以下簡稱「天津星魅」）正式投入運營。天津星魅於近期宣佈其與以色列Raziel Therapeutics (RT) Ltd.（以下簡稱「Raziel」）訂立許可協議，獲得在中國大陸及港澳臺地區獨家臨床開發和商業化其注射類產品RZL012的權利。RZL-012是第一款運用於美容和治療的具有長效作用的單次治療注射產品。
復銳醫療科技董事長劉毅先生表示：「新的區域辦公室將繼續踐行復銳醫療科技的經營理念，我們將利用區域業務的協同優勢，爲醫美健康市場提供一整套的解決方案。」
復銳醫療科技首席執行官Lior Dayan表示：「中國是我們全球戰略的重點，天津辦公室的設立表明了我們在中國，及亞太地區發展的雄心和規劃。未來幾年我們將致力於在中國和來自全球的跨國和本土企業拓展新的業務。」
關於復銳醫療科技
復銳醫療科技（股份代號：1696.HK）是能量源醫療美容行業全球前五的領導者之一，是中國領先的醫療健康產業集團復星醫藥的控股子公司。復銳醫療科技於2017年9月19日在香港上市，是第一家在香港聯合交易所主板上市的以色列公司。其核心子公司Alma Lasers是全球領先的能量源外科和醫療美容設備提供商，在全球90多個國家和地區開展業務。公司旗艦產品包括：（i）[Soprano]系列，主要用於激光脫毛；（ii）[Harmony]系列，可用於超過65種FDA許可適應症的多功能多應用平台；（iii）[Accent]系列，主要用於美體塑形及緊膚，全部均屬醫療美容產品線；（iv）[FemiLift]，一種用於多種女性問題的微創醫療美容器械；及（v）[BeautiFill] by LipoFlow 平台，FDA批准的首個、也是目前唯一用於自體脂肪移植的能量源設備。此外，公司也進入了注射劑市場，並在以色列及中國香港均有銷售。
復銳醫療科技 提高生活質量
媒體聯繫人
中國：
Edmond Lococo 董事總經理
ICR Asia
+86 (10) 6583-7510
Edmond.lococo@icrinc.com
Sisram Medical Expands its APAC Operation, Opening a New Regional Office in Tianjin, China
Sisram Medical Ltd ("Sisram" or "the Company") (Hong Kong: 1696), an operational holding company specializing in medical aesthetics technology for wellness, today announced the expansion of its business with a new office to serve China and the greater Asia Pacific region.
Sisram Medical’s newly established office in China will handle various business activities addressing the evolving ecosystem and potential synergies between Sisram and its majority shareholder, Fosun Pharma (Fosun Pharma, stock code: 600196.SH, 02196.HK). Amongst the first activities the new office will oversee are: aesthetic dentistry, registration of dermal facial fillers with China’s National Medical Products Administration (NMPA), and the establishment of a regional service center and regional warehouse.
Sisram Medical’s new regional office is located in China’s Tianjin Pilot Free Trade Zone and will be headed by Mr. Liu Yi, the Chairman of Sisram Medical, and President of the Medical Devices Division of Fosun Pharma. The appointment of Mr. Liu Yi is a testament to Fosun Pharma’s trust and the importance of its future plans for Sisram Medical’s business operation in China and the greater APAC region.
The Tianjin office was launched with a first investment in a start-up company that was incubated by Fosun Pharma’s venture capital fund. The startup company, named Tianjin JuveStar Biotech Co., Ltd., (JuveStar), recently announced the signing of a license agreement with Raziel Therapeutics.
The agreement provides JuveStar with exclusive rights to develop and commercialize Raziel's proprietary RZL-012, an exciting injectable product for aesthetic indications and additional therapeutic fields, in mainland China, Hong Kong, Macau and Taiwan. RZL-012 is the first, long-lasting single treatment injectable product for aesthetic and therapeutic applications.
"The new regional office echoes Sisram's philosophy by providing an umbrella of solutions for the wellness market, leveraging our synergistic strengths and local business affiliation" said Mr. Liu
Lior Dayan, Sisram Medical CEO said, "China is a global strategic priority for us. The opening of our local office in Tianjin is a clear statement of the company’s ambitious growth plans for the country in specific, and the region in general. We are committed to develop new and additional business with international and Chinese companies in China in the coming years."
About Sisram Medical Ltd
Sisram Medical Ltd (1696.HK) is one of the top 5 global leaders in the energy-based medical aesthetics industry. The company is majority held by Fosun Pharma, a leading healthcare group in China. Sisram Medical successfully went public on September 19, 2017, as the first Israeli company listed on the Hong Kong Exchange Main Board. Sisram Medical’s core subsidiary, Alma, is a global leading provider of energy-based surgical and medical aesthetics solutions and is active across over 90 countries and jurisdictions worldwide. Flagship systems of Sisram Medical include (i) the 「Soprano」 family, primarily used for laser hair removal; (ii) the 「Harmony」 family, a versatile multi-application platform that can be used to treat more than 65 different FDA-cleared indications; (iii) the 「Accent」 family, primarily used for body contouring and skin tightening; (iv) 「FemiLift」, a minimally invasive treatment system for various feminine conditions; and (v) 「BeautiFill」 by LipoFlow platform, the first and only energy-based device cleared by the FDA for autologous fat grafting. In addition, Sisram Medical also entered the injectables market, with products available in Israel and Hong Kong.
Sisram Medical – Enhancing Quality of Life.
For media inquiries, please contact:
ICR Inc.
Edmond Lococo
Tel: +86 (10) 6583-7510
E-mail: Edmond.lococo@icrinc.com
風險及免責聲明：以上內容僅代表作者個人觀點，不代表富途任何立場，亦不構成任何投資建議，富途對此不作任何保證與承諾。更多信息
評論
發表評論
1